Senseonics Acquires Eversense U.S. Assets, Reshapes Partnership

Senseonics Holdings ( (SENS) ) has issued an announcement.

On December 31, 2025, Senseonics Holdings and its subsidiary Senseonics, Inc. signed a master asset purchase agreement with Ascensia Diabetes Care Holdings to acquire certain U.S. assets related to the marketing, selling and distribution of the Eversense CGM product, with the U.S. asset purchase closing on January 1, 2026 for approximately $1.1 million in cash, along with the assumption of related liabilities, including transferred contracts and certain employees. The parties also plan, subject to local agreements and regulatory and contractual closing conditions, to acquire additional commercial Eversense assets in Italy, Germany, Spain and Sweden by June 30, 2026, while an amended and restated collaboration and commercialization agreement effective January 1, 2026 terminates Ascensia’s U.S. marketing rights, makes its European rights non-exclusive, and shifts 100% of Eversense revenues in Europe to Senseonics, marking a strategic move to internalize global commercial operations; concurrently, PHC Holdings executive Koichiro Sato resigned from Senseonics’ board, and PHC signaled it does not currently intend to designate a new director despite retaining the right to do so.

The most recent analyst rating on (SENS) stock is a Hold with a $6.50 price target. To see the full list of analyst forecasts on Senseonics Holdings stock, see the SENS Stock Forecast page.

Spark’s Take on SENS Stock

According to Spark, TipRanks’ AI Analyst, SENS is a Neutral.

Senseonics Holdings faces significant financial challenges, with high leverage and negative profitability metrics being the most impactful risks. Despite positive revenue growth and successful marketing strategies, the stock’s bearish technical indicators and poor valuation metrics weigh heavily on its overall score.

To see Spark’s full report on SENS stock, click here.

More about Senseonics Holdings

Senseonics Holdings, Inc. is a medical technology company focused on diabetes care, developing and commercializing the Eversense family of continuous glucose monitoring (CGM) systems. The company’s primary products include implantable CGM sensors and related software, with a market focus on patients requiring long-term, continuous glucose monitoring in the United States and key European markets such as Italy, Germany, Spain and Sweden.

Average Trading Volume: 528,598

Technical Sentiment Signal: Sell

Current Market Cap: $225.5M

For a thorough assessment of SENS stock, go to TipRanks’ Stock Analysis page.